Oslo Cancer Cluster
Oslo Cancer Cluster is a Norwegian non-profit membership cluster founded in 2006 that brings together ~100 biotech, pharma, research, and healthcare organizations to accelerate oncology innovation through its co-located incubator, Innovation Park, CONNECT precision-medicine consortium, school collaboration program, and EU Mission on Cancer advocacy.
- Company typePrivate
- Founded2006
- HeadquartersOslo, Norway
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Oslo Cancer Cluster does
Oslo Cancer Cluster SA is a non-profit membership-based research and industry cluster founded in 2006 and headquartered in the Oslo Cancer Cluster Innovasjonspark (OCCI), on a campus co-located with the Norwegian Radium Hospital, parts of Oslo University Hospital, the Cancer Registry of Norway, Ullern Upper Secondary School, and approximately 30 incubator companies. The cluster serves roughly 100 member organizations spanning biotech, pharmaceutical, research, and healthcare stakeholders, and its stated mission is to shorten the time required to develop new cancer medicines and treatments by brokering cross-sectoral research collaborations, public-private partnerships, and EU Mission on Cancer contributions.
The organization's core services center on (i) the Oslo Cancer Cluster Incubator, which provides state-of-the-art laboratory facilities and business support to oncology start-ups (incubated companies include EasySun AS for cancer prevention and Zelluna for TCR-NK cell therapy); (ii) the Oslo Cancer Cluster Innovation Park, a physical campus leveraging the Radiumhospitalet heritage, currently planning a Lamell 4 expansion; (iii) the CONNECT consortium, a 29-partner public-private coordination effort for implementing precision cancer medicine across all Norwegian university hospitals, which the cluster coordinates; (iv) the long-running School Collaboration Program with Ullern Upper Secondary School (since 2009, with over 10,000 students/teachers engaged and 539 placements) and the Forskerlinja researcher program; and (v) policy advocacy through direct submissions to the Storting, ministries, and directorates on health and research framework conditions.
The business model is subscription/membership-based with annual fees paid by member companies and institutions; pricing is not publicly disclosed and total revenue is not reported. The cluster is governed as a Norwegian non-profit (SA) with a board drawn from universities, hospitals, biotechs, global pharma, and patient organizations. It co-founded Cancer Mission Hub Norway (2022) with the Norwegian Cancer Society and the Research Council of Norway, holds Gold Label status as an NCE Health Cluster from Norwegian Innovation Cluster, and is one of the owners of HealthCatalyst AS, a cross-cluster initiative to position Norway as a global health-technology testbed.
Oslo Cancer Cluster firmographics
Firmographics- Name
- Oslo Cancer Cluster
- Legal name
- Oslo Cancer Cluster SA
- Website
- https://oslocancercluster.no
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Oslo Cancer Cluster is a Norwegian non-profit membership cluster founded in 2006 that brings together ~100 biotech, pharma, research, and healthcare organizations to accelerate oncology innovation through its co-located incubator, Innovation Park, CONNECT precision-medicine consortium, school collaboration program, and EU Mission on Cancer advocacy.
- Ownership category
- akta.pro rank
Oslo Cancer Cluster industry classification
Industry- Product category
- Oncology Research Cluster Services
- NAICS
- Business Associations (813910), Other Similar Organizations (except Business, Professional, Labor, and Political Organizations) (81399)
- SIC
- Services-Membership Organizations (8600), Services-Health Services (8000)
- akta.pro primary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
Keywords
Where Oslo Cancer Cluster is headquartered
LocationHeadquarters
- HQ city
- Oslo
- HQ country
- Norway
- HQ region
- Europe
Offices1 record
Markets served
Oslo Cancer Cluster business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Membership Fees: Oslo Cancer Cluster generates revenue through membership fees from biotech companies, pharmaceutical firms, research institutions, and healthcare organizations. Membership provides access to network, events, courses, and promotional opportunities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Standard membership with full benefits |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Oslo Cancer Cluster product offering
Product offeringCore offering
Oslo Cancer Cluster operates a membership-based cancer innovation cluster that supports biotechnology companies, pharmaceutical firms, and research institutions in developing new cancer treatments and diagnostics. Core offerings include the Incubator (state-of-the-art laboratories and start-up support), the Innovation Park campus at the Norwegian Radium Hospital, the CONNECT precision medicine consortium, EU Mission on Cancer activities, and education programs.
Product overview
Oslo Cancer Cluster is a non-profit research and industry cluster that aims to shorten the time it takes to develop new medicines and treatments for cancer. Established in 2006 with approximately 100 members, the organization offers a portfolio of services including the Oslo Cancer Cluster Incubator (providing laboratory facilities and business support for start-ups), the Oslo Cancer Cluster Innovation Park (a collaborative campus at the Norwegian Radium Hospital), and the School Collaboration Program with Ullern videregående skole. The cluster coordinates the CONNECT consortium for precision medicine implementation and contributes to EU Mission on Cancer. Core activities span research partnerships, public-private collaborations, EU activities, start-up services, policy advocacy, and education initiatives. Notable incubated companies include EasySun AS (cancer prevention through sunscreen dispensers) and Zelluna (off-the-shelf cell therapy for solid tumors).
Differentiator
Problem solved
Functional benefit
Brands
- CONNECT: Konsortium for innføring av kreftpresisjonsmedisin (Consortium for the introduction of cancer precision medicine) coordinated by Oslo Cancer Cluster.
Products and services
- Oslo Cancer Cluster Incubator Dynamic, creative, and professional growth environment providing state-of-the-art laboratories and business support services for scientists and oncology-focused start-ups; offers an inspirational campus for students with ambitions in life science. Members gain access to incubation facilities, mentorship, and ecosystem connections.
- Oslo Cancer Cluster Innovation Park (OCCI) Unique campus facility built on private enthusiasm and the long history of cancer research at the Norwegian Radium Hospital; houses member companies, research institutions, Ullern Upper Secondary School, Kreftregisteret, and parts of Oslo universitetssykehus in a collaborative innovation campus.
- CONNECT Consortium Public-private consortium accelerating the introduction of precision medicine in cancer treatment across Norway. Coordinated by Oslo Cancer Cluster with 29 partners spanning all Norwegian university hospitals, pharma companies, technology firms, the Norwegian Cancer Society, Institute of Public Health, and Health Directorate.
- School Collaboration Program with Ullern Upper Secondary School Long-running education and talent-pipeline program inspiring secondary-school students toward careers in life science research and entrepreneurship. Includes career days, student research placements, and the Forskerlinja (researcher program). Has engaged over 10,000 students and teachers since 2009.
- Health Catalyst Cross-cluster initiative owned by gold-labelled NCE Health Clusters (including Oslo Cancer Cluster) that aims to build Norway as a global test site and innovation centre for future health technology and services.
- National Policy Input Service Cluster service that contributes expert input to Norwegian health, research, and industry policies through submissions to the Storting, ministries, and directorates, addressing framework conditions for cancer innovation.
Quantifiable outcome
- 10,206 students and teachers participated in school collaboration projects since 2009
- +3 more outcomes
Companies that use Oslo Cancer Cluster
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
Oslo Cancer Cluster technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Oslo Cancer Cluster partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered strategic, core and minor.
- SweCan (Sweden's Cancer Mission Hub)strategicNordic collaboration with new Swedish cancer mission hub launched in Stockholm. Delegates from Norway's Cancer Mission Hub attended the opening to share learnings and strengthen Nordic cooperation in cancer research and care.
- Berlin Center for Gene and Cell TherapiesstrategicCollaboration on whitepaper 'Bridging the Gaps: Unlocking the Future of Advanced Therapies in Europe via Novel Alliances.' High-level expert roundtable hosted at Nordic Embassies in Berlin, bringing together voices from Europe's ATMP ecosystem.
- CONNECT ConsortiumcoreCONNECT is a public-private consortium for implementing precision medicine in cancer treatment in Norway. With 29 partners including all Norwegian university hospitals, pharmaceutical and technology companies, Kreftforeningen, Folkehelseinstituttet, and Helsedirektoratet. Coordinated by Oslo Cancer Cluster.
- Norwegian Cancer SocietycoreCo-founder of Cancer Mission Hub Norway in 2022, along with Research Council of Norway and Oslo Cancer Cluster. Works in close collaboration with key players from Norwegian cancer ecosystem to support national and European cancer efforts.
- Ullern Upper Secondary SchoolcoreLong-standing school collaboration established in 2009, with co-location in Oslo Cancer Cluster Innovasjonspark since 2015. The collaboration includes career days, research placements, Forskerlinja (researcher program), and mentorship. Over 10,000 students and teachers have participated, with 539 students completing placements. In 2025, the collaboration celebrated 15 years.
- Radforsk InvesteringsstiftelsecoreCo-organizer of Arendalsuka 2026 events including Campus Radiumhospitalet discussions and kick-off mingling. Radforsk's CEO Jónas Einarsson is co-founder of Oslo Cancer Cluster.
- Oslo Science HubcoreCo-organizer of Arendalsuka 2026 events. Co-located in Oslo Cancer Cluster Innovasjonspark area, contributing to the innovation ecosystem around Radiumhospitalet.
- Kreftforeningen (Norwegian Cancer Society)coreCo-organizer of 'Fremtidens kreftbehandling' (Future Cancer Treatment) seminar series and Arendalsuka 2026 events. Partner in CONNECT consortium for precision medicine implementation.
- LMI (Association of the Pharmaceutical Industry)strategicCo-organizer of 'Fremtidens kreftbehandling' seminar series and Arendalsuka 2026 events. Collaboration on clinical trials policy discussions.
- Norway Health TechstrategicCo-organizer of 'Norge 2030: Ambisjoner holder ikke' event at Arendalsuka 2026. Part of broader health tech ecosystem collaboration.
- The Life Science ClusterstrategicCo-organizer of 'Norge 2030: Ambisjoner holder ikke' event at Arendalsuka 2026. Part of Norwegian life science cluster collaboration.
- EasySun ASminorStart-up in Oslo Cancer Cluster Incubator developing sunscreen dispensers for cancer prevention. EasySun received support from Janne Nestvold and Thomas Andersson in the Incubator for establishing the company, seeking financial support, and practical issues.
- Oslo University HospitalcoreKreftklinikken (Cancer Clinic) at Oslo University Hospital is co-located in Oslo Cancer Cluster Innovasjonspark and collaborates on research, clinical trials, and events including Arendalsuka.
- Thermo Fisher ScientificcoreFeatured member and tenant in Oslo Cancer Cluster Innovasjonspark. Thermo Fisher Scientific's Norwegian office is located in the innovation park area and participates in school collaboration programs.
- HealthCatalyststrategicHealthCatalyst AS is owned by gold-labelled NCE Health Clusters including Oslo Cancer Cluster. It aims to build Norway as a global test site for health technology, with Ketil Widerberg from Oslo Cancer Cluster on the board.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Oslo Cancer Cluster competitors and assessment
Company assessmentDirect peers
- BioM Biotech Cluster Development GmbH: Bavarian biotech cluster organization supporting startups, SMEs, and pharma in the Munich region with incubator-style services, networking, and internationalization — directly comparable to OCC as a German regional biotech cluster.
- Medicon Village: Swedish life-science innovation park and cluster in Lund that hosts biotech companies, research, and incubator activities — a close Nordic analogue to OCC's innovation-park-plus-cluster model.
- FlandersBio: Belgian life-sciences cluster association representing biotech, pharma, and research organizations — comparable as a European national cluster body supporting member networking and policy advocacy.
- BioInnovation Institute (BII): Danish non-profit biotech incubator and venture creation facility that supports early-stage life-science companies with lab space, mentorship, and venture funding — comparable in mission and structure to OCC's incubator.
- The Life Science Cluster (Norway): Norwegian life-science cluster that collaborates with OCC on events and is a peer national cluster organization with overlapping member ecosystems and shared policy engagement in Norway.
- Karolinska Innovations: Sweden's innovation arm linked to Karolinska Institutet that commercializes life-science research and supports biotech startups — directly comparable as a Nordic academic/biotech commercialization and incubation entity.
- Munich Biotech Cluster (m4 Cluster): Bavarian personalized-medicine and biotech cluster that supports startups, pharma collaborations, and academic partnerships — directly comparable to OCC's oncology-and-precision-medicine cluster role.
Emerging players
- SciLifeLab: Swedish national life-science research infrastructure supporting genomics, precision medicine, and translational research — a partial-overlap peer given OCC's precision-medicine mandate via CONNECT.
Broad incumbents
- BIO Deutschland: German biotechnology industry association providing advocacy, networking, and member services to the broader biotech sector — comparable in mission as a sector-wide membership and policy body, but operating nationally in Germany rather than regionally.
Regional players
- Norwegian Smart Care Cluster: Norwegian health-technology cluster with overlapping policy networks and Arendalsuka collaborations with OCC — a regional health-innovation cluster peer within Norway.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Oslo Cancer Cluster social profiles
Digital presenceOslo Cancer Cluster financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oslo Cancer Cluster leadership team
Management profileNumber of profiles
Profiles5 records
Oslo Cancer Cluster funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oslo Cancer Cluster M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oslo Cancer Cluster
What does Oslo Cancer Cluster do?
Oslo Cancer Cluster operates a membership-based cancer innovation cluster that supports biotechnology companies, pharmaceutical firms, and research institutions in developing new cancer treatments and diagnostics. Core offerings include the Incubator (state-of-the-art laboratories and start-up support), the Innovation Park campus at the Norwegian Radium Hospital, the CONNECT precision medicine consortium, EU Mission on Cancer activities, and education programs.
Is Oslo Cancer Cluster a public or private company?
Oslo Cancer Cluster is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Oslo Cancer Cluster founded?
Oslo Cancer Cluster was founded in 2006. It employs 1 to 10 people.
Where is Oslo Cancer Cluster based?
Oslo Cancer Cluster is headquartered in Oslo, Norway, in the Europe region.
How does Oslo Cancer Cluster make money?
One revenue line is on record: membership Fees.
Who are Oslo Cancer Cluster's main competitors?
Direct peers on record are BioM Biotech Cluster Development GmbH, Medicon Village, FlandersBio, BioInnovation Institute (BII), The Life Science Cluster (Norway), Karolinska Innovations and Munich Biotech Cluster (m4 Cluster). SciLifeLab is listed as an emerging player. BIO Deutschland is listed as a broad incumbent. Norwegian Smart Care Cluster is listed as a regional player.
Does Oslo Cancer Cluster have an API?
No public API is recorded for Oslo Cancer Cluster.
What industry is Oslo Cancer Cluster in?
Oslo Cancer Cluster's product category is Oncology Research Cluster Services. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 813910 and its SIC code is 8600.